Global Market Directs pharmaceuticals report, Eurocine Vaccines AB Product Pipeline Review 2012 provides data on the Eurocine Vaccines ABs research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Eurocine Vaccines ABs corporate website, SEC filings, investor presentations and featured press releases, both from Eurocine Vaccines AB and industry-specific third party sources, put together by Global Markets Directs team. 

• Eurocine Vaccines AB Brief Eurocine Vaccines AB overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of Eurocine Vaccines AB human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of Eurocine Vaccines AB with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
• Recent updates of the Eurocine Vaccines ABs pipeline in the last quarter. 
• Key discontinued and dormant projects. 
• Latest news and deals relating to the products.

• Evaluate Eurocine Vaccines ABs strategic position with total access to detailed information on its product pipeline. 
• Assess the growth potential of Eurocine Vaccines AB in its therapy areas of focus. 
• Identify new drug targets and therapeutic classes in the Eurocine Vaccines ABs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
• Exploit collaboration and partnership opportunities with Eurocine Vaccines AB. 
• Avoid Intellectual Property Rights related issues. 
• Explore the dormant and discontinued projects of Eurocine Vaccines AB and identify potential opportunities in those areas.

Table of Contents 2
List of Tables 3
List of Figures 3
Eurocine Vaccines AB Snapshot 4
Eurocine Vaccines AB Overview 4
Key Information 4
Key Facts 4
Eurocine Vaccines AB Research and Development Overview 5
Key Therapeutic Areas 5
Eurocine Vaccines AB Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products Monotherapy 8
Eurocine Vaccines AB Pipeline Products Glance 9
Eurocine Vaccines AB Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Eurocine Vaccines AB Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Eurocine Vaccines AB Drug Profiles 11
Immunose FLU 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Nasal Pneumococcal Vaccine 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Eurocine Vaccines AB Pipeline Products by Route of Administration 14
Eurocine Vaccines AB Recent Pipeline Updates 15
Eurocine Vaccines AB Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Eurocine Vaccines AB, Recent Developments 17
Eurocine Vaccines AB- Press Release 17
Jan 04, 2012: Eurocine Vaccines, Bionor Pharma And Oslo University Announce Full Enrollment Of Nasal Immunization Study Of Vacc4x And Endocine 17
Dec 03, 2009: Eurocine Vaccines Clinical Trial Fully Recruited 17
Oct 07, 2009: Eurocine Vaccines Begins Nasal Influenza Vaccine Study In Humans 18
Financial Deals Landscape 19
Eurocine Vaccines AB, Deals Summary 19
Eurocine Vaccines AB, Pharmaceuticals & Healthcare, Deal Details 20
Partnerships 20
Eurocine Vaccines Enters Into Collaboration With HeliCure 20
Equity Offering 21
Eurocine Vaccines Completes Private Placement Of Shares For $1.8 Million 21

Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23